SLC5A2 and type 2 diabetes mellitus: Meta-regression analysis sought to identify potential sources of heterogeneity, considering baseline EF, type of SGLT2 inhibitors, follow-up time (≤ 26 weeks, 26–52 weeks, > 52 weeks) participant age (≤ 65 years, > 65 years), and whether patients were complicated with T2D.